SEC Form 4 · accession 0001615774-18-003641
Emmaus Life Sciences, Inc. · EMMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George C Carpenter IV
Officer — Chief Executive Officer
Period of report
Sep 18, 2017
Accepted (ET)
May 11, 2018 · 5:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822370
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to purchase)F1 | $3.53 | Sep 18, 2017 | A | 100,000 | A | Sep 18, 2017 | Sep 18, 2027 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1On September 18, 2017, the reporting person was granted an option to purchase 100,000 shares of common stock. The grant of these options was contingent upon shareholder approval of an amendment to MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan (the "Plan") at the Company's 2018 Annual Meeting of Shareholders, increasing the total number of shares available for grant and an increase to the evergreen provision of the Plan. Such shareholder approval was obtained at the Company's 2018 Annual Meeting of Shareholders on April 4, 2018. The option vests in ten installments based on the reporting person's satisfaction of certain performance criteria. One of the ten milestones have been satisfied.